Protective effect of N-benzoyl-beta-alanine against cisplatin nephrotoxicity in rats. 1996

J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
Department of Pharmacy, Kumamoto University Hospital, Japan.

Prophylactic effects of N-benzoyl-beta-alanine (betamipron, BP), one of a series of N-acyl amino acids, were examined against cisplatin-induced nephrotoxicity. Male Wistar rats were injected i.p. with 6 mg/kg of cisplatin combined with an i.p. BP dose given at various times and various doses. Rats were sacrificed 5 days after cisplatin injection to weigh the kidney and liver, and to determine blood urea nitrogen (BUN) and serum creatinine (serum Cr) levels. Preliminary results suggest that treatment with BP is an effective means of protection against cisplatin-induced nephrotoxicity. Combination with BP reduced the weight loss following treatment with cisplatin. The ratios of the kidney and liver weights to the body weight in the animals treated with cisplatin followed later with BP are significantly different (p < 0.05) from those in the animals that received only cisplatin. The BUN and serum Cr levels in the animals treated with cisplatin followed from -1 to 4 hr, and from -4 to 4 hr later with 250 mg/kg BP dose and followed 1 hr later with from 250 to 1000 mg/kg, and from 250 to 2000 mg/kg BP doses differed significantly (p < 0.05) from those in the animals that received only cisplatin. Histological analysis of the kidneys confirmed the protective effect of BP.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
August 2014, Human & experimental toxicology,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
January 2017, Drug design, development and therapy,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
December 2019, Journal of advanced veterinary and animal research,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
July 2008, Pakistan journal of pharmaceutical sciences,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
April 1989, Antimicrobial agents and chemotherapy,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
April 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
January 2013, Indian journal of pharmacology,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
July 2016, Canadian journal of physiology and pharmacology,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
June 2017, BMC nephrology,
J Tokunaga, and M Kobayashi, and C Nakamura, and A Kitagawa, and K Arimori, and M Nakano
June 2002, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP,
Copied contents to your clipboard!